{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:11:04Z","timestamp":1785564664505,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1038\/s41416-018-0261-0","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T13:38:47Z","timestamp":1536845927000},"page":"707-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Everolimus and pazopanib (E\/P) benefit genomically selected patients with metastatic urothelial carcinoma"],"prefix":"10.1038","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":false,"given":"Joaquim","family":"Bellmunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9907-9112","authenticated-orcid":false,"given":"Aly-Khan A.","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sussana","family":"Jacobus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Wankowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Polacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-1588","authenticated-orcid":false,"given":"Lauren C.","family":"Harshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Wagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Boss\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"261_CR1","doi-asserted-by":"crossref","unstructured":"Iyer G., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.","DOI":"10.1126\/science.1226344"},{"key":"261_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1053\/j.seminoncol.2012.08.004","volume":"39","author":"S Sadeghi","year":"2012","unstructured":"Sadeghi, S. & Garcia, A. J. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. Semin. Oncol. 39, 608\u2013614 (2012).","journal-title":"Semin. Oncol."},{"key":"261_CR3","doi-asserted-by":"publisher","first-page":"e18583","DOI":"10.1371\/journal.pone.0018583","volume":"6","author":"G Sj\u00f6dahl","year":"2011","unstructured":"Sj\u00f6dahl, G. et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS. ONE. 6, e18583 (2011).","journal-title":"PLoS. One."},{"key":"261_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/hmg\/dds486","volume":"22","author":"SV Williams","year":"2013","unstructured":"Williams, S. V., Hurst, C. D. & Knowles, M. A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795\u2013803 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"261_CR5","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2012.46.8934","volume":"31","author":"LA Garraway","year":"2013","unstructured":"Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806\u20131814 (2013).","journal-title":"J. Clin. Oncol."},{"key":"261_CR6","first-page":"258","volume":"69","author":"Fus \u0141P","year":"2016","unstructured":"\u0141P, Fus, G\u00f3rnicka & Role, B. of angiogenesis in urothelial bladder carcinoma. Cent. Eur. J. Urol. 69, 258\u2013263 (2016).","journal-title":"Cent. Eur. J. Urol."},{"key":"261_CR7","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","volume":"90","author":"CB Ching","year":"2010","unstructured":"Ching, C. B. & Hansel, D. E. Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway. Lab. Investig. 90, 1406\u20131414 (2010).","journal-title":"Lab. Investig."},{"key":"261_CR8","first-page":"3038","volume":"46","author":"T O\u2019Reilly","year":"2005","unstructured":"O\u2019Reilly, T. et al. Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: A rational basis for combining RAD001 and PTK787\/ZK222584. Proc. Annu. Meet. Am. Assoc. Cancer Res. 46, 3038 (2005).","journal-title":"Proc. Annu. Meet. Am. Assoc. Cancer Res."},{"key":"261_CR9","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/j.1349-7006.2006.00263.x","volume":"97","author":"T Ikezoe","year":"2006","unstructured":"Ikezoe, T. et al. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: Enhancement of growth inhibition via inhibition of 3- kinase\/Akt\/mammalian target of rapamycin signaling. Cancer Sci. 97, 945\u2013951 (2006).","journal-title":"Cancer Sci."},{"key":"261_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-161","volume":"9","author":"E Juengel","year":"2009","unstructured":"Juengel, E. et al. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. Bmc. Cancer 9, 161 (2009).","journal-title":"Bmc. Cancer"},{"key":"261_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","volume":"11","author":"J LoPiccolo","year":"2008","unstructured":"LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B. & Dennis, P. A. Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32\u201350 (2008).","journal-title":"Drug Resist. Updat."},{"key":"261_CR12","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1097\/JTO.0b013e3182614835","volume":"7","author":"VA Papadimitrakopoulou","year":"2012","unstructured":"Papadimitrakopoulou, V. A. et al. Everolimus and erlotinib as second- or thirdline therapy in patients with advanced non-small-cell lung cancer. J. Thorac. Oncol. 7, 1594\u20131601 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"261_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s10637-015-0238-2","volume":"33","author":"HV Rodrigues","year":"2015","unstructured":"Rodrigues, H. V. et al. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive\/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest. New Drugs 33, 700\u2013709 (2015).","journal-title":"Invest. New Drugs"},{"key":"261_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","volume":"4","author":"N Wagle","year":"2014","unstructured":"Wagle, N. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4, 546\u2013553 (2014).","journal-title":"Cancer Discov."},{"key":"261_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"261_CR16","doi-asserted-by":"publisher","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","volume":"1","author":"LM Sholl","year":"2016","unstructured":"Sholl, L. M. et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 1, e87062 (2016).","journal-title":"JCI Insight"},{"key":"261_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1081\/CNV-120003536","volume":"20","author":"J Bellmunt","year":"2002","unstructured":"Bellmunt, J. et al. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 20, 673 (2002).","journal-title":"Cancer Invest."},{"key":"261_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005392-200101000-00017","volume":"165","author":"S Krege","year":"2001","unstructured":"Krege, S., Rembrink, V., B\u00f6rgermann, C., Otto, T. & Rubben, H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J. Urol. 165, 67 (2001).","journal-title":"J. Urol."},{"key":"261_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/CAD.0b013e3280126603","volume":"18","author":"CC Lin","year":"2007","unstructured":"Lin, C. C. et al. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 18, 487 (2007).","journal-title":"Anticancer Drugs"},{"key":"261_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/j.1442-2042.2007.01831.x","volume":"14","author":"N Soga","year":"2007","unstructured":"Soga, N., Onishi, T., Arima, K. & Sugimura, Y. Paclitaxel Carboplatin chemotherapy as a second- line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int. J. Urol. 14, 828 (2007).","journal-title":"Int. J. Urol."},{"key":"261_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/jjco\/hyp003","volume":"39","author":"T Suyama","year":"2009","unstructured":"Suyama, T. et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn. J. Clin. Oncol. 39, 244 (2009).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"261_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/annonc\/mdq398","volume":"22","author":"P Albers","year":"2011","unstructured":"Albers, P. et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20\/99]. Ann. Oncol. 22, 288 (2011).","journal-title":"Ann. Oncol."},{"key":"261_CR23","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"261_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma, P. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single- arm, phase 2 trial. Lancet Oncol. 18, 312\u2013322 (2017).","journal-title":"Lancet Oncol."},{"key":"261_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"261_CR26","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"Thomas Powles","year":"2017","unstructured":"Powles T., et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study. JAMA Oncol. 2017: e172411.","journal-title":"JAMA Oncology"},{"key":"261_CR27","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","volume":"35","author":"AB Apolo","year":"2017","unstructured":"Apolo, A. B. et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J. Clin. Oncol. 35, 2117\u20132124 (2017).","journal-title":"J. Clin. Oncol."},{"key":"261_CR28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40265-017-0748-7","volume":"77","author":"MS Farina","year":"2017","unstructured":"Farina, M. S., Lundgren, K. T. & Bellmunt, J. Immunotherapy in urothelial carcinoma: recent results and future perspectives. Drugs 77, 1077\u20131089 (2017).","journal-title":"Drugs"},{"key":"261_CR29","unstructured":"Powles T. IMvigor211: A phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma. EACR-AACR-SIC Special Conference. June 24-27, 2017, Florence, Italy, abstract 606."},{"key":"261_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network.","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315 (2014).","journal-title":"Nature"},{"key":"261_CR31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cncr.29826","volume":"122","author":"JS Ross","year":"2016","unstructured":"Ross, J. S. et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer 122, 702\u2013711 (2016).","journal-title":"Cancer"},{"key":"261_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20080281","volume":"412","author":"J Huang","year":"2008","unstructured":"Huang, J. & Manning, B. The TSC1\u2013TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412, 179\u2013190 (2008).","journal-title":"Biochem. J."},{"key":"261_CR33","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies, D. M. et al. Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial. Clin. Cancer Res. 17, 4071\u20134081 (2011).","journal-title":"Clin. Cancer Res."},{"key":"261_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler, J. J. et al. Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140\u2013151 (2008).","journal-title":"N. Engl. J. Med."},{"key":"261_CR35","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1200\/JCO.2010.32.7825","volume":"29","author":"HJ Kl\u00fcmpen","year":"2011","unstructured":"Kl\u00fcmpen, H.-J. et al. mTOR Inhibitor Treatment of Pancreatic Cancer in a Patient With Peutz-Jeghers Syndrome. J. Clin. Oncol. 29, e150\u2013e153 (2011).","journal-title":"J. Clin. Oncol."},{"key":"261_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner, N. & Grose, R. Fibroblast growth factor signaling: from development to cancer. Nat. Rev. Cancer 10, 116\u2013129 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"261_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","volume":"3","author":"YM Wu","year":"2013","unstructured":"Wu, Y. M. et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636\u2013647 (2013).","journal-title":"Cancer Discov."},{"key":"261_CR38","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/1541-7786.MCR-15-0497","volume":"14","author":"KN Nelson","year":"2016","unstructured":"Nelson, K. N. et al. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation. Mol. Cancer Res. 14, 458\u2013469 (2016).","journal-title":"Mol. Cancer Res."},{"key":"261_CR39","doi-asserted-by":"crossref","first-page":"26374","DOI":"10.18632\/oncotarget.8380","volume":"7","author":"CH Chen","year":"2016","unstructured":"Chen, C. H. et al. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo. Oncotarget 7, 26374\u201326387 (2016).","journal-title":"Oncotarget"},{"key":"261_CR40","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1158\/1541-7786.MCR-14-0004","volume":"12","author":"J Acquaviva","year":"2014","unstructured":"Acquaviva, J. et al. FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism. Mol. Cancer Res. 12, 1042\u20131054 (2014).","journal-title":"Mol. Cancer Res."},{"key":"261_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.eururo.2015.02.023","volume":"68","author":"N Palma","year":"2015","unstructured":"Palma, N., Morris, J. C., Ali, S. M., Ross, J. S. & Pal, S. K. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification. Eur. Urol. 68, 168\u2013170 (2015).","journal-title":"Eur. Urol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0261-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0261-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0261-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:19Z","timestamp":1684616599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0261-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0261-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"5 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.B.: Honoraria\/consulting from Astellas, Genentech, Merck, Novartis, Pfizer, Pierre Fabre; institutional research funding\/support from Millenium, Sanofi, MSD Oncology, Pfizer. A.A.L.: Honoraria\/consulting from Novartis; travel expenses from Pfizer. L.C.H.: Honoraria\/consulting from Genentech, Pfizer, Dendreon, NCCN, Medivation\/Astellas, KEW; institutional research funding\/support from Bayer, Medivation\/Astellas, Pfizer, Dendreon, Sotio, Genentech, Merck, BMS, Jannsen. E.M.V.A.: Honoraria\/consulting from Genome Medical, Novartis, Roche, Syapse, Takeda, Third Rock Ventures; institutional research funding\/support from Bristol-Myers Squibb, Novartis. T.K.C.: Honoraria\/consulting from Alligent, AstraZeneca, Bayer, Bristol-Myers Squibb, Cerulean Pharma, Eisai, Exelixis, Foundation Medicine, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus, Roche\/Genentech; institutional research funding\/support from Pfizer, Exelixis, Bristol-Myers Squibb, Novartis, Peloton, AstraZeneca, Agensys, TRACON. J.E.R.: Honoraria\/consulting from Agensys, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol- Myers Squibb, EMD Serono, Lilly, Merck, Oncogenex, Roche\/Genentech, Sanofi, Seattle Genetics; institutional research funding\/support from Agensys, Genentech\/Roche, Mirati Therapeutics, Novartis, Oncogenex, Viralytics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted with Dana-Farber\/Harvard Cancer Center institutional review board approval in accordance with the Declaration of Helsinki and Good Clinical Practice and was registered with the National Institutes of Health (NCT01184326). Patients provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data and materials are available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Availability of data and material"}},{"value":"This work was supported by Novartis in the setting of an Investigator Initiated Study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Funding"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}